Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. KPRX
KPRX logo

KPRX Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Kiora Pharmaceuticals Inc (KPRX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
2.530
1 Day change
-1.56%
52 Week Range
3.390
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Kiora Pharmaceuticals Inc (KPRX) does not present a strong buy opportunity for a long-term beginner investor at this time. The technical indicators are neutral to slightly bearish, there are no significant trading trends or positive catalysts, and no recent financial or valuation data is available to support a confident investment decision.

Technical Analysis

The MACD histogram is negative and expanding (-0.0216), indicating bearish momentum. RSI is neutral at 43.042, and moving averages are converging, suggesting no clear trend. The stock is trading below the pivot level (2.574), with key support at 2.475 and resistance at 2.674.

Positive Catalysts

  • NULL identified. No recent news or significant trading trends from hedge funds or insiders.

Neutral/Negative Catalysts

  • Bearish technical indicators, lack of financial data, and a projected negative price trend (-1% in the next week, -3.81% in the next month).

Financial Performance

No financial data available for analysis due to an error in the provided data.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target changes available for KPRX.

Wall Street analysts forecast KPRX stock price to rise
1 Analyst Rating
Wall Street analysts forecast KPRX stock price to rise
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.570
sliders
Low
12
Averages
12
High
12
Current: 2.570
sliders
Low
12
Averages
12
High
12
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$10
AI Analysis
2025-07-22
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$10
AI Analysis
2025-07-22
maintain
Buy
Reason
H.C. Wainwright reiterates a Buy rating and $10 price target on shares of Kiora Pharmaceuticals after the company announced that it received received a U.S. patent covering KIO-104 for the treatment of ocular diseases, including ocular inflammation, uveitis, age-related macular degeneration, and complications from refractive surgery. The patent covers varying dosing schedules, necessary excipients, and other novel methods for optimizing treatment of ocular inflammatory diseases, the analyst tells investors in a research note. The new patent should strengthen the company's IP portfolio and help secure the potential market prospects if KIO-104 is successfully developed in clinical studies, the firm says.

People Also Watch